Literature DB >> 205305

Reactions after pertussis vaccine: a manufacturer's experiences and difficulties since 1964.

A H Griffith.   

Abstract

Pertussis vaccines vary in quality, safety, and efficacy according to the production strains of Bordetella pertussis, the method of manufacture, and quality control procedures. It is therefore not justifiable to combine information on the incidence, nature, and severity of reactions after all manufacturers' pertussis vaccines as if they were a single product. Attempts were made to collect information on all suspected cases of severe reactions that occurred after administration of about 15 million doses of Wellcome pertussis vaccines in the United Kingdom and Northern Ireland from 1964 to mid-1977. Altogether six deaths, six neurological reactions with sequelae, and 17 convulsions without sequelae were reported, but some were clearly not attributable to the vaccine, while, in other cases, the available information was inadequate for assessing the role of vaccination. Neurological disorders, similar to those reported in a few children after pertussis vaccination, occur unexpectedly in apparently healthy infants at the recommended age for immunisation, so chance association between vaccination and these events can be expected in some children. The Joint Committee on Vaccination and Immunisation has made several recommendations aimed at reducing severe reactions after pertussis vaccination. These include replacing plain vaccine with aluminium-adsorbed vaccine, but there is no clear evidence that the aluminium-adsorbed vaccine produces fewer reactions than the plain.There are difficulties enough in deciding the cause of events that occur after vaccination, since these reactions often occur naturally in children of vaccination age. The task is made even harder by the assumption that various manufacturers' vaccines are the same and the lack of information available to manufacturers about cases in which their vaccine has been implicated. Information on vaccines administered is entered on immunisation records cards; it should be used and referred to if reactions occur.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 205305      PMCID: PMC1603528          DOI: 10.1136/bmj.1.6116.809

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


  54 in total

1.  EFFECTIVENESS OF PERTUSSIS VACCINES.

Authors:  N W PRESTON
Journal:  Br Med J       Date:  1965-07-03

2.  Antigenic modulation of Bordetella pertussis.

Authors:  B W LACEY
Journal:  J Hyg (Lond)       Date:  1960-03

3.  The phase I of Haemophilus pertussis.

Authors:  A F B STANDFAST
Journal:  J Gen Microbiol       Date:  1951-08

4.  Trial of Whooping-cough Vaccine.

Authors:  A M McFarlan; E Topley; M Fisher
Journal:  Br Med J       Date:  1945-08-18

5.  Pertussis Vaccine Prepared with Phase-I Cultures Grown in Fluid Medium.

Authors:  S M Cohen; M W Wheeler
Journal:  Am J Public Health Nations Health       Date:  1946-04

6.  Mouse Protection Tests in the Study of Pertussis Vaccine: A Comparative Series Using the Intracerebral Route for Challenge.

Authors:  P L Kendrick; G Eldering; M K Dixon; J Misner
Journal:  Am J Public Health Nations Health       Date:  1947-07

7.  Active Immunization Against Whooping Cough : Interim Report of the Cleveland Experience.

Authors:  J A Doull; G S Shibley; J E McClelland
Journal:  Am J Public Health Nations Health       Date:  1936-11

8.  Comparison of pertussis cultures by mouse protection and virulence tests .

Authors:  P L KENDRICK; E L UPDYKE; G ELDERING
Journal:  Am J Public Health Nations Health       Date:  1949-02

9.  Instability of pertussis-vaccine component in quadruple antigen vaccine. Diphtheria and tetanus toxoids and pertussis and poliomyelitis vaccines.

Authors:  M PITTMAN
Journal:  JAMA       Date:  1962-07-07       Impact factor: 56.272

10.  PERTUSSIS VACCINE TESTING FOR FREEDOM-FROM-TOXICITY.

Authors:  M PITTMAN; C B COX
Journal:  Appl Microbiol       Date:  1965-05
View more
  7 in total

1.  Should public health take over immunization?

Authors:  P C Lai; A K Leung
Journal:  Can Fam Physician       Date:  1985-01       Impact factor: 3.275

Review 2.  Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies.

Authors:  Seema Mattoo; James D Cherry
Journal:  Clin Microbiol Rev       Date:  2005-04       Impact factor: 26.132

3.  Whooping cough and pertussis vaccine.

Authors:  G T Stewart
Journal:  Br Med J (Clin Res Ed)       Date:  1983-07-23

4.  Whooping cough immunization in France and Britain: discussion paper.

Authors:  E M Ross; L Edouard
Journal:  J R Soc Med       Date:  1983-05       Impact factor: 5.344

5.  Immunization of children in Calgary.

Authors:  A Leung
Journal:  Can Med Assoc J       Date:  1984-10-15       Impact factor: 8.262

6.  Whooping cough and pertussis vaccination.

Authors: 
Journal:  Br Med J (Clin Res Ed)       Date:  1983-12-17

7.  Two physically and serologically distinct lipopolysaccharide profiles in strains of Bordetella pertussis and their phenotype variants.

Authors:  M S Peppler
Journal:  Infect Immun       Date:  1984-01       Impact factor: 3.441

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.